The FDA has approved Boehringer Ingelheim's nerandomilast as a treatment for idiopathic pulmonary fibrosis (IPF), giving the company a successor to its blockbuster therapy Ofev. Phosphodiesterase (PDE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback